MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, MGX had $5,923K increase in cash & cash equivalents over the period. -$21,327K in free cash flow.

Cash Flow Overview

Change in Cash
$5,923K
Free Cash flow
-$21,327K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Maturities of available-for-sale...
    • Accrued expenses and other curre...
    • Stock-based compensation expense
    • Others
Negative Cash Flow Breakdown
    • Net loss
    • Deferred revenue and collaborati...
    • Purchases of available-for-sale ...
    • Others

Cash Flow
2025-09-30
2025-06-30
Net loss
-20,393 -44,947
Stock-based compensation expense
3,010 6,149
Depreciation
1,324 2,693
Loss on fixed assets write-off
0 181
Non-cash lease expense
1,272 2,664
Accretion of premiums and discounts on available-for-sale marketable securities
705 1,825
Amortization of non-cash collaboration revenue
125 87
Income tax payable
-0
Change in fair value of long-term investments
0 1,292
Accounts receivable
87 -384
Prepaid expenses and other assets
-1,140 -2,687
Accounts payable
-1,576 2,284
Deferred revenue and collaboration advance
-7,574 -10,417
Accrued expenses and other current liabilities
4,023 -2,476
Operating lease liabilities
-1,328 -2,818
Other non-current liabilities
-234 143
Net cash used in operating activities
-21,253 -44,093
Purchases of property and equipment
74 415
Proceeds from sale of property and equipment
0 37
Purchases of available-for-sale marketable securities
6,063 40,796
Maturities of available-for-sale marketable securities
33,500 84,974
Net cash provided by (used in) investing activities
27,363 43,800
Proceeds from issuance of common stock upon initial public offering, net of underwriting discounts and commissions and other offering costs
-0
Proceeds from issuance of common stock under the equity incentive plan and espp
109 -
Payment of deferred financing costs
187 352
Proceeds from issuance of common stock under espp
-109
Net cash provided by (used in) financing activities
-187 -243
Net increase (decrease) in cash, cash equivalents and restricted cash
5,923 -536
Cash and cash equivalents at beginning of period
32,634 -
Cash and cash equivalents at end of period
38,021 -
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Maturities ofavailable-for-sale marketable...$33,500K Net cash provided by(used in) investing...$27,363K Canceled cashflow$6,137K Net increase(decrease) in cash, cash...$5,923K Canceled cashflow$21,440K Purchases ofavailable-for-sale marketable...$6,063K Purchases of property andequipment$74K Accrued expenses andother current...$4,023K Stock-based compensationexpense$3,010K Depreciation$1,324K Non-cash lease expense$1,272K Prepaid expenses andother assets-$1,140K Proceeds from issuance ofcommon stock under the...$109K Net cash used inoperating activities-$21,253K Net cash provided by(used in) financing...-$187K Canceled cashflow$10,769K Canceled cashflow$109K Net loss-$20,393K Deferred revenue andcollaboration advance-$7,574K Payment of deferredfinancing costs$187K Accounts payable-$1,576K Operating leaseliabilities-$1,328K Accretion of premiums anddiscounts on...$705K Other non-currentliabilities-$234K Amortization of non-cashcollaboration revenue$125K Accounts receivable$87K something is missing-$109K

MGX

MGX